Page last updated: 2024-09-04

cyc 202 and can 508

cyc 202 has been researched along with can 508 in 3 studies

Compound Research Comparison

Studies
(cyc 202)
Trials
(cyc 202)
Recent Studies (post-2010)
(cyc 202)
Studies
(can 508)
Trials
(can 508)
Recent Studies (post-2010) (can 508)
97973931009

Protein Interaction Comparison

ProteinTaxonomycyc 202 (IC50)can 508 (IC50)
Chain A, Cyclin-dependent kinase 9Homo sapiens (human)0.74
Cyclin-T1Homo sapiens (human)0.31
G1/S-specific cyclin-E2Homo sapiens (human)3.5
Cyclin-dependent kinase 1Homo sapiens (human)0.35
Cyclin-dependent kinase 4Homo sapiens (human)0.35
G2/mitotic-specific cyclin-B1Homo sapiens (human)0.35
Cyclin-A2Homo sapiens (human)0.35
Ribosomal protein S6 kinase beta-1Homo sapiens (human)10
G1/S-specific cyclin-D1Homo sapiens (human)0.35
G1/S-specific cyclin-E1Homo sapiens (human)1.925
Cyclin-dependent kinase 2Homo sapiens (human)1.4
Cyclin-dependent kinase 7Homo sapiens (human)0.35
Cyclin-dependent kinase 9Homo sapiens (human)0.3214
Cyclin-HHomo sapiens (human)0.35
Ribosomal protein S6 kinase beta-2Homo sapiens (human)10

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's1 (33.33)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Cankar, P; de Azevedo, WF; Dzubák, P; Fischer, PM; Frysová, I; Hajdúch, M; Kontopidis, G; Krystof, V; Látr, A; Orság, M; Paprskárová, M; Rolcík, J; Slouka, J; Srovnal, J; Strnad, M1
Baumli, S; Endicott, JA; Fischer, PM; Hole, AJ; Huang, S; Noble, ME; Pepper, C; Shao, H; Shi, S; Wang, S1
Abdel-Aziz, HA; Abou-Seri, SM; Bonardi, A; Eldehna, WM; Elgazar, AA; Fahim, SH; Gratteri, P; Kryštof, V; Nocentini, A; Said, MA; Soliman, DH; Supuran, CT1

Other Studies

3 other study(ies) available for cyc 202 and can 508

ArticleYear
4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
    Journal of medicinal chemistry, 2006, Nov-02, Volume: 49, Issue:22

    Topics: Antimetabolites; Azo Compounds; Bromodeoxyuridine; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinases; Enzyme Inhibitors; Humans; Immunoblotting; Models, Molecular; Pyrazoles; Reverse Transcriptase Polymerase Chain Reaction; Reverse Transcription; RNA; Structure-Activity Relationship; Substrate Specificity

2006
Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity.
    Journal of medicinal chemistry, 2013, Feb-14, Volume: 56, Issue:3

    Topics: Cyclin-Dependent Kinase 9; Humans; Models, Molecular; Protein Kinase Inhibitors; Pyrimidines; Structure-Activity Relationship

2013
Sulfonamide-based ring-fused analogues for CAN508 as novel carbonic anhydrase inhibitors endowed with antitumor activity: Design, synthesis, and in vitro biological evaluation.
    European journal of medicinal chemistry, 2020, Mar-01, Volume: 189

    Topics: Antineoplastic Agents; Azo Compounds; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Humans; In Vitro Techniques; Molecular Docking Simulation; Molecular Structure; Neoplasms; Pyrazoles; Structure-Activity Relationship; Sulfonamides

2020